Bio Protocol Secures Major Funding to Advance Decentralized Biotech Research
Bio Protocol, a decentralized science (DeSci) platform, has closed a $6.9 million funding round. Investors include Maelstrom Fund and Animoca Brands. The financing highlights rising interest in decentralized and AI-driven approaches to scientific research and drug discovery.
Investment Led by Notable Crypto and Venture Players
The funding round underscores growing support for the integration of artificial intelligence, blockchain technology, and community engagement in biotech. Arthur Hayes, founder of Maelstrom Fund, called Bio Protocol a potential �category-defining launchpad� in research. Hayes suggested the platform could enable new research opportunities prioritized by community interest, not only traditional academic standards.
Decentralized Research Through Blockchain and AI
Bio Protocol aims to accelerate drug discovery by blending crypto incentives with decentralized governance models. The platform employs AI-based agents known as �BioAgents� that can form hypotheses, interact with onchain wallets, and allocate community-raised capital to experiments. All research steps are recorded onchain, creating a transparent and unalterable record. This ensures contributors are properly credited for their work.
The protocol uses tokenized intellectual property, a staking system, and loyalty rewards to align the interests of investors, researchers, and community members. These crypto-native incentives are designed to keep research activity moving efficiently.
Part of the Expanding DeSci Movement
Bio Protocol positions itself within the larger DeSci movement, which looks to change the way scientific research is conducted, funded, and shared. DeSci uses crypto tools and decentralized structures to reduce reliance on universities, government grants, and pharmaceutical companies while making research more accessible to independent scientists and communities.
Simon Dedic, founder of Moonrock Capital and an early investor, noted that DeSci is at an early stage but sees projects like Bio Protocol as potentially transformative. He cited his experience in academic science and said existing systems suffer from misaligned incentives that hamper progress. Dedic believes Bio Protocol could help alleviate these challenges and improve the scientific research landscape.
Bio Protocol�s new funding is expected to expand its AI-native framework and further develop decentralized tools for the biotech community.
Related content
Comments
